These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24444519)

  • 21. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity and Diabetes.
    Aberle J; Lautenbach A; Meyhöfer S; Schmid SM; Selig L; Blüher M
    Exp Clin Endocrinol Diabetes; 2021 Aug; 129(S 01):S44-S51. PubMed ID: 33352596
    [No Abstract]   [Full Text] [Related]  

  • 23. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
    Diabetes Care; 2018 Dec; 41(12):2669-2701. PubMed ID: 30291106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
    Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
    Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
    Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology of type 2 diabetes and its relationship to new therapeutic approaches.
    Bell D
    Diabetes Educ; 2000; 26 Suppl():4-7. PubMed ID: 11912815
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification.
    O'Keefe EL; Sturgess JE; O'Keefe JH; Gupta S; Lavie CJ
    Am J Cardiol; 2021 Dec; 160():46-52. PubMed ID: 34583808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical and surgical management of obesity and diabetes: what's new?
    Ammori BJ; Skarulis MC; Soran H; Syed AA; Eledrisi M; Malik RA
    Diabet Med; 2020 Feb; 37(2):203-210. PubMed ID: 31850536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.
    Deol H; Lekkakou L; Viswanath AK; Pappachan JM
    Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
    Lundkvist P; Sjöström CD; Amini S; Pereira MJ; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity and type 1 diabetes mellitus management.
    Chillarón JJ; Benaiges D; Mañé L; Pedro-Botet J; Flores Le-Roux JA
    Minerva Endocrinol; 2015 Mar; 40(1):53-60. PubMed ID: 25413942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
    Hurren KM; Dunham MW
    Expert Opin Pharmacother; 2018 Jul; 19(10):1087-1095. PubMed ID: 29958007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
    Shaikh S; Rizvi SM; Shakil S; Riyaz S; Biswas D; Jahan R
    Biotechnol Appl Biochem; 2016; 63(1):145-50. PubMed ID: 25402624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
    Kilov G; Leow S; Thomas M
    Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.